BRENTWOOD, Tenn. / Nov 05, 2024 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
A live audio webcast of the fireside chat discussions will be available at the Investor Relations section of the Company’s website, at https://ir.ardenthealth.com, and a replay will be available for 90 days using the same link.
In conjunction with these conferences, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend each conference. For more information, please contact your sales representative at the host firm, or Dave Styblo, Ardent Health’s senior vice president of investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$11.78 |
Daily Change: | -0.33 -2.73 |
Daily Volume: | 241,898 |
Market Cap: | US$1.680B |
March 31, 2025 February 26, 2025 November 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load